About Ishares Nasdaq Biotechnology (NASDAQ:IBB)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Basic Details
Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A
Fund Focus
Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$8.90 billion
Average Daily Volume$2.74 million
Discount/Premium-1.41%
ETF Expenses
Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%
Administrator, Advisor and Custodian
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial
Ishares Nasdaq Biotechnology (NASDAQ:IBB) Frequently Asked Questions
What is Ishares Nasdaq Biotechnology's stock symbol?
Ishares Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "IBB."
How often does Ishares Nasdaq Biotechnology pay dividends? What is the dividend yield for Ishares Nasdaq Biotechnology?
Ishares Nasdaq Biotechnology announced a quarterly dividend on Thursday, December 21st. Investors of record on Friday, December 22nd will be given a dividend of $0.125 per share on Thursday, December 28th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Thursday, December 21st. This is an increase from Ishares Nasdaq Biotechnology's previous quarterly dividend of $0.04. View Ishares Nasdaq Biotechnology's Dividend History.
When did Ishares Nasdaq Biotechnology's stock split? How did Ishares Nasdaq Biotechnology's stock split work?
Ishares Nasdaq Biotechnology's stock split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were payable to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of Ishares Nasdaq Biotechnology stock prior to the split would have 300 shares after the split.
Who are some of Ishares Nasdaq Biotechnology's key competitors?
Some companies that are related to Ishares Nasdaq Biotechnology include DNP Select Income Fund (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity (ADX), Tri Continental (TY), Gabelli Equity Trust (GAB), Tortoise Energy Infrastructure (TYG), PIMCO Cor & Inc Opp Fds (PTY), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Apollo Investment (AINV), Boulder Growth & Income Fund (BIF), Hercules Technology Growth Capital (HTGC), PIMCO High Income Fund (PHK), Alliance World Dollar Government Fund II (AWF) and Solectron (SLRC).
Who are Ishares Nasdaq Biotechnology's key executives?
Ishares Nasdaq Biotechnology's management team includes the folowing people:
- George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
- Michael Arthur Latham, President, Trustee
- Jack Gee, Chief Financial Officer, Treasurer
- Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
- , Bio & Compensation -
- Amy Schioldager, Executive Vice President
- Ira P. Shapiro, Vice President, Chief Legal Officer
- Matt Tucker, Vice President
- , Bio & Compensation -
- Eilleen M. Clavere, Secretary
- Cecilia H. Herbert, Independent Trustee
- Charles A. Hurty, Independent Trustee
Has Ishares Nasdaq Biotechnology been receiving favorable news coverage?
News stories about IBB stock have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ishares Nasdaq Biotechnology earned a media sentiment score of 0.15 on Accern's scale. They also assigned news articles about the financial services provider an impact score of 46.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Ishares Nasdaq Biotechnology's major shareholders?
Ishares Nasdaq Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Natixis (1.38%), Royal Bank of Canada (1.07%), Commerce Bank (0.97%), Clal Insurance Enterprises Holdings Ltd (0.91%), PNC Financial Services Group Inc. (0.79%) and LPL Financial LLC (0.61%). View Institutional Ownership Trends for Ishares Nasdaq Biotechnology.
Which institutional investors are selling Ishares Nasdaq Biotechnology stock?
IBB stock was sold by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Psagot Investment House Ltd., BB&T Securities LLC, NF Trinity Capital Hong Kong Ltd, The Manufacturers Life Insurance Company , PNC Financial Services Group Inc., Blair William & Co. IL and Analyst IMS Investment Management Services Ltd.. View Insider Buying and Selling for Ishares Nasdaq Biotechnology.
Which institutional investors are buying Ishares Nasdaq Biotechnology stock?
IBB stock was purchased by a variety of institutional investors in the last quarter, including Natixis, State of Tennessee Treasury Department, First Republic Investment Management Inc., Commerzbank Aktiengesellschaft FI, LPL Financial LLC, Graham Capital Management L.P., Cheyne Capital Management UK LLP and Timber Hill LLC. View Insider Buying and Selling for Ishares Nasdaq Biotechnology.
How do I buy shares of Ishares Nasdaq Biotechnology?
Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ishares Nasdaq Biotechnology's stock price today?
One share of IBB stock can currently be purchased for approximately $106.72.
How big of a company is Ishares Nasdaq Biotechnology?
Ishares Nasdaq Biotechnology has a market capitalization of $9.07 billion.
MarketBeat Community Rating for Ishares Nasdaq Biotechnology (IBB)
MarketBeat's community ratings are surveys of what our community members think about Ishares Nasdaq Biotechnology and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ishares Nasdaq Biotechnology (NASDAQ:IBB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | Buy | Buy |
| Consensus Rating Score: | N/A | N/A | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Ishares Nasdaq Biotechnology (NASDAQ:IBB) Consensus Price Target History
Show:
Ishares Nasdaq Biotechnology (NASDAQ:IBB) Dividend Information
Ishares Nasdaq Biotechnology pays an annual dividend of $0.42 per share, with a dividend yield of 0.39%. IBB's most recent quarterly dividend payment was Thursday, December 28.
| Most Recent Dividend: | 12/28/2017 |
| Annual Dividend: | $0.42 |
| Dividend Yield: | 0.39% |
| Payout Ratio(s): | N/A |
Ishares Nasdaq Biotechnology (NASDAQ:IBB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/21/2017 | Quarterly | $0.1250 | 0.47% | 12/21/2017 | 12/22/2017 | 12/28/2017 |
| 9/26/2017 | Quarterly | $0.0397 | 0.14% | 9/26/2017 | 9/27/2017 | 9/29/2017 |
| 6/27/2017 | quarterly | $0.0589 | 0.23% | 6/27/2017 | 6/29/2017 | 6/30/2017 |
| 3/24/2017 | quarterly | $0.0997 | 0.41% | 3/24/2017 | 3/28/2017 | 3/30/2017 |
| 12/22/2016 | quarterly | $0.0306 | 0.14% | 12/22/2016 | 12/27/2016 | 12/29/2016 |
| 6/24/2015 | quarterly | $0.0193 | 0.06% | 6/24/2015 | 6/26/2015 | 6/30/2015 |
(Data available from 1/1/2013 forward)
Ishares Nasdaq Biotechnology (NASDAQ:IBB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
